4.5 Article

Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science

期刊

HEADACHE
卷 49, 期 -, 页码 S21-S33

出版社

WILEY
DOI: 10.1111/j.1526-4610.2008.01336.x

关键词

triptans; migraine epidemiology; pathophysiology

资金

  1. AGA
  2. Advanced NeuroModulation Systems
  3. Allergan, Boston Scientific
  4. Coherex
  5. Endo Pharmaceuticals
  6. GlaxoSmithKline
  7. Lilly
  8. MAP
  9. Medtronic
  10. Merck
  11. NuPath
  12. Valeant Pharmaceuticals
  13. Almirall
  14. CoLucid
  15. Eisai
  16. Linde
  17. Menarini
  18. NWO
  19. NIH
  20. European Community FPG
  21. Biomed EC
  22. Dutch Heart Foundation

向作者/读者索取更多资源

The triptan era has been a time of remarkable progress for migraine diagnosis and treatment. In this paper, we review some of the advances achieved in migraine science during this era focusing on 3 themes: lessons from clinical practice, lessons from epidemiology and lessons from pathophysiology. Science has shown that migraine is a disorder of the brain, and that the key events happen in the the trigeminal neuronal pathways, not on blood vessels. Clinical science has led to the observation that migraine sometimes progresses or remits. This in turn led to longitudinal epidemiologic studies focusing on factors that determine migraine prognosis. In addition, these studies raised questions about the mechanisms of migraine progression, including the role of allodynia, obesity, inflammation, and medications as determinants of progression. This in turn opens a new set of scientific questions about the neurobiologic determinants of migraine, as well as of its clinical course, and exciting opportunities to develop new therapies for this highly disabling brain disorder.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据